Laura Van ‘t Veer, PhD

Laura Van ‘t Veer, PhD

Laura Van ‘t Veer, PhD

Laura van ‘t Veer received her M.Sc. degree in Biology (1984) at the University of Amsterdam and a PhD in Medicine (1989) at the University of Leiden, The Netherlands. She did her postdoctoral training at the Cancer Center of the Harvard Medical School and The Massachusetts General Hospital, Boston, USA (1989-1991) and The Netherlands Cancer Institute (1992-1993). From 1993 till 2007 she initiated and held the positions of Head Molecular Pathology and Head Genetic Counseling Clinic at the Netherlands Cancer Institute. In 2003 she was one of the founders of the Netherlands Cancer Institute spin-off, the molecular profiling company Agendia. In 2007-2010 she became Division Head Diagnostic Oncology, including clinical operations and research of 5 clinical departments. Since 2010 she is Professor at the University of California San Francisco, where she leads the Breast Oncology Program. Dr. van ‘t Veer is first author of a study showing that microarray genomics technology can predict which breast tumors will likely metastasize and which will not (Nature 2002, NEJM 2002). When these findings are implemented into daily clinical practice, the amount of so-called adjuvant treatments with chemotherapy for (pre-menopausal) breast cancer patients could be reduced by up to thirty percent. This microarray test now called MammaPrint, is central to the work of the translational research network TRANSBIG (Translational Research Breast International Group). The MINDACT trial is worldwide the first large scale clinical trial implementing genomics. MammaPrint is an FDA cleared In Vitro Diagnostic Multigene Index Assay (IVDMIA), included in several international and national guidelines for breast cancer management. At UCSF she coordinates the tissue and biomarker activities of the FNIH sponsored multicenter adaptive clinical trial I-SPY. Dr. van ‘t Veer received for this work the 2007 European Society of Medical Oncology (ESMO) life-time achievement award for translational research in breast cancer.

Connect With Us
Join other physicians who are receiving our updates.
We hate spam. Your email address will not be sold or shared with anyone else.